-+ 0.00%
-+ 0.00%
-+ 0.00%

Perspective Therapeutics Announces First Patient Treated With PSV359 In Phase 1/2A Dose-Finding Trial Assessing Safety And Preliminary Anti-Tumor Activity

Benzinga·04/29/2025 11:04:21
Listen to the news

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359.